New Alzheimer’s Drug Deemed Too Costly for UK’s State-run Health Service
NICE also cited a lack of evidence on the long-term effects of taking the treatment, noting that the clinical trial only reported outcomes when people had been taking lecanemab for 18 months
New Alzheimer’s Drug Deemed Too Costly for UK’s State-run Health Service Read More »